- DocumentBiomarkers in Parkinson’s disease (recent update) (1).pdfuploaded byAndré Alcântara
- DocumentAmaral et al., 2019 DDT Animal venoms therapeutic tools foruploaded byAndré Alcântara
- Document(2014-Aviles-Olmos, I.) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's diseaseuploaded byAndré Alcântara
- Document2022 GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-artuploaded byAndré Alcântara
- DocumentJEJUMuploaded byAndré Alcântara
- Documentimg20210726_18032686uploaded byAndré Alcântara
- Documentimg20210628_14274594uploaded byAndré Alcântara
- Documentimg20210628_14284013uploaded byAndré Alcântara
- Documentimg20210726_18002796uploaded byAndré Alcântara
- Documentimg20210726_18041393uploaded byAndré Alcântara
- Documentimg20210628_14264541uploaded byAndré Alcântara